Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Upper Gastrointestinal Cancer

Treatments: Drug: Nivolumab

Study type: Observational

Funder types: Industry

Identifiers

NCT06361576

CA209-1443

Details and patient eligibility

About

The purpose of this observational study is to describe the demographics, and disease characteristics of participants with metastatic upper gastrointestinal cancer, along with the treatment characteristics of these patients when treated with nivolumab.

Enrollment: 700 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Enrolled in the Bristol-Myers Squibb GastroEsophageal Opdivo in non-Resectable, advanced or metastatic Adenocarcinoma Patient Support Program (GEORgiA PsP) in Canada
• Have consented to the use of their de-identified data generated from information collected during the course of the GEORgiA PsP

Exclusion criteria

• Aged <18 years
• HER2 positive status
• Untreated brain metastases

Trial design

700 participants in 1 patient group

Participants enrolled and treated with nivolumab in the metastatic setting

Treatment:

Drug: Nivolumab